citric acid, anhydrous has been researched along with Gonorrhea in 1 studies
Citric Acid: A key intermediate in metabolism. It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium chelating ability.
citric acid : A tricarboxylic acid that is propane-1,2,3-tricarboxylic acid bearing a hydroxy substituent at position 2. It is an important metabolite in the pathway of all aerobic organisms.
Gonorrhea: Acute infectious disease characterized by primary invasion of the urogenital tract. The etiologic agent, NEISSERIA GONORRHOEAE, was isolated by Neisser in 1879.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chappell, BT | 1 |
| Mena, LA | 1 |
| Maximos, B | 1 |
| Mollan, S | 1 |
| Culwell, K | 1 |
| Howard, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 2B Double-blind Placebo-controlled Efficacy Trial of EVO100 (Previously Known as Amphora ® Gel) for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection[NCT03107377] | Phase 2/Phase 3 | 860 participants (Actual) | Interventional | 2017-11-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Summary of Coital Events during treatment (NCT03107377)
Timeframe: 16 weeks
| Intervention | Coital Events (Mean) |
|---|---|
| EVO100 | 15.7 |
| Placebo | 16.3 |
Summary of number of applicators used via eDiary (NCT03107377)
Timeframe: 16 weeks
| Intervention | Number of Applicators (Mean) |
|---|---|
| EVO100 | 13.0 |
| Placebo | 13.5 |
Study product adherence (NCT03107377)
Timeframe: 16 weeks
| Intervention | % of sex acts where study product used (Mean) |
|---|---|
| EVO100 | 78.9 |
| Placebo | 78.3 |
Proportion of subjects who experience urogenital CT infection during the study intervention period (incident infection of CT). (NCT03107377)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| EVO100 | 14 |
| Placebo | 28 |
Proportion of subjects who experience urogenital GC infection during the study intervention period (incident infection of GC). (NCT03107377)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| EVO100 | 2 |
| Placebo | 9 |
1 trial available for citric acid, anhydrous and Gonorrhea
| Article | Year |
|---|---|
EVO100 prevents chlamydia and gonorrhea in women at high risk of infection.
Topics: Administration, Intravaginal; Adult; Anti-Infective Agents; Chlamydia Infections; Citric Acid; Drug | 2021 |